KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Payables (2018 - 2025)

Historic Payables for Aurinia Pharmaceuticals (AUPH) over the last 10 years, with Q3 2025 value amounting to $2.2 million.

  • Aurinia Pharmaceuticals' Payables fell 9610.01% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year decrease of 9610.01%. This contributed to the annual value of $5.2 million for FY2024, which is 1987.52% up from last year.
  • Latest data reveals that Aurinia Pharmaceuticals reported Payables of $2.2 million as of Q3 2025, which was down 9610.01% from $3.3 million recorded in Q2 2025.
  • Aurinia Pharmaceuticals' Payables' 5-year high stood at $56.8 million during Q3 2024, with a 5-year trough of $2.2 million in Q3 2025.
  • Moreover, its 5-year median value for Payables was $32.4 million (2022), whereas its average is $29.8 million.
  • Per our database at Business Quant, Aurinia Pharmaceuticals' Payables soared by 8936.29% in 2021 and then plummeted by 9610.01% in 2025.
  • Quarter analysis of 5 years shows Aurinia Pharmaceuticals' Payables stood at $34.9 million in 2021, then grew by 14.43% to $40.0 million in 2022, then crashed by 89.18% to $4.3 million in 2023, then rose by 19.88% to $5.2 million in 2024, then tumbled by 57.32% to $2.2 million in 2025.
  • Its last three reported values are $2.2 million in Q3 2025, $3.3 million for Q2 2025, and $4.2 million during Q1 2025.